A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
Opening soon Phase 3 NCT07664553
Run by AstraZeneca · for 18 and older · All sexes
What this study is about
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)
Who can join (things the study team will check)
✅ You may be able to join if…
- Diagnosed with T2DM for at least 90 days prior to screening
- Stable treatment with background insulin and other background glucose-lowering medication(s)
- HbA1c value of ≥ 7% to ≤ 10.5%
- Body mass index (BMI) of ≥ 23 kg/m2 at screening
- Stable body weight (self-reported or documented) for 90 days prior to screening
🚫 You may not be able to join if…
- T1DM, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
- Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
- Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
- Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
- History of acute or chronic pancreatitis.
- Severe congestive heart failure (NYHA IV)
- History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Where this trial is running
- Research Site, Little Rock, Arkansas, United States
- Research Site, Lincoln, California, United States
- Research Site, Aurora, Colorado, United States
- Research Site, Ocoee, Florida, United States
- Research Site, Decatur, Georgia, United States
- Research Site, Potomac, Maryland, United States
- Research Site, Cary, North Carolina, United States
- Research Site, Morehead City, North Carolina, United States
- Research Site, Myrtle Beach, South Carolina, United States
- Research Site, Memphis, Tennessee, United States
- Research Site, Houston, Texas, United States
- Research Site, San Antonio, Texas, United States
+ 108 more sites.
Who to contact
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07664553.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.